BTIG initiated coverage of NRx Pharmaceuticals (NRXP) with a Buy rating and $18 price target NRx Pharmaceuticals is working broadly in ...

Fintel reports that on March 31, 2025, BTIG upgraded their outlook for Progyny (NasdaqGS:PGNY) from Neutral to Buy. Analyst ...

Meeting to be held in Dallas on April 8 hosted by BTIG.Don't Miss Our End of Quarter Offers: Discover the latest stocks recommended by top Wall ...

BTIG analysts highlighted a historical trend suggesting a potential rebound for the S&P 500 (SPX) in April following a ...

Investing.com -- BTIG downgraded Ally Financial (NYSE:ALLY) Inc to Sell from Neutral with a $30 target saying a challenging macroeconomic condition and increased competition in the auto lending ...

BTIG Research assumed coverage on shares of Super Group (NYSE:SGHC – Free Report) in a research note published on Friday, Marketbeat Ratings reports. The firm issued a buy rating and a $9.00 ...

Friday’s stock market slide will likely cement the S&P 500 and Nasdaq Composite’s seventh weekly decline in nine weeks. The S ...

CrowdStrike (CRWD) was upgraded from Neutral to Buy by BTIG, and maintains a $431 price target on the stock. Market Domination hosts Julie Hyman and Josh Lipton break down BTIG's reasons for the ...

Lululemon Athletica (NASDAQ:LULU – Free Report) had its price objective decreased by BTIG Research from $470.00 to $420.00 in ...

On Monday, BTIG analysts maintained a Neutral rating on Venus Concept Inc. (NASDAQ:VERO) after the company reported lower-than-expected Q4 revenue. Venus Concept disclosed a quarterly revenue of $ ...